Vaccine against severe fever with thrombocytopenia syndrome virus
The SNAP technology addresses the challenge of immunogenicity and stability in SFTS vaccines by using CoPoP liposomes to non-covalently display SFTSV antigens, achieving effective immune responses and preventing SFTS virus infection.
Patent Information
- Application Number
- PCT/US2026/028693
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-18
- Publication Date
- 2026-11-19
AI Technical Summary
Current technologies lack effective vaccines against Severe Fever with Thrombocytopenia Syndrome (SFTS) virus, which is transmitted by ticks and has caused significant outbreaks in Asia and is spreading, with limited immunogenicity of recombinant protein antigens and challenges in stable antigen presentation.
The use of spontaneous nanoliposome antigen particles (SNAP) technology, where cobalt-porphyrin-phospholipid (CoPoP) liposomes non-covalently associate with polyhistidine-tagged SFTSV antigens, such as Gn or Gc proteins, displaying them on the liposome surface, combined with adjuvants like MPLA and QS-21, to enhance immunogenicity and elicit neutralizing antibodies.
The SNAP technology provides stable and immunogenic presentation of SFTSV antigens, inducing robust immune responses and neutralizing antibodies, effectively inhibiting SFTSV infection and disease.
Smart Images

Figure US2026028693_19112026_PF_FP_ABST
Abstract
Description
Attorney Docket No.: 011520.02070VACCINE AGAINST SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The instant application claims the benefit of priority to U.S. Provisional Application No. 63 / 807,516, filed on May 16, 2025, the disclosure of which is incorporated herein by reference.SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing, which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 18, 2026, is named “011520_02070_ST26.xml”, and is 15,210 bytes in size.BACKGROUND OF THE DISCLOSURE
[0003] Severe Fever with Thrombocytopenia Syndrome (SFTS) is an emerging zoonotic hemorrhagic fever caused by SFTS virus (SFTSV; or Dabie bandavirus), a tick-borne bunyavirus mostly transmitted by Asian longhomed ticks, which have now spread beyond Asia, with incidences of human -to-human transmission. SFTS has become prevalent in China, Japan, and Korea, with tens of thousands of cases emerging since 2010, with cases also reported in Vietnam and Myanmar.
[0004] Spontaneous Nanoliposome Antigen Particle (SNAP) technology was discovered with the observation that cobalt-porphyrin-phospholipid (CoPoP) incorporation into liposomes gives rise to spontaneous and stable display of his-tagged proteins on liposome surfaces, yielding enhancement in immunogenicity for many recombinant protein antigens.SUMMARY OF THE DISCLOSURE
[0005] The present disclosure provides compositions, systems, and methods for generating immune responses against Severe Fever with Thrombocytopenia Syndrome virus (SFTSV). The disclosed compositions generally employ a spontaneous nanoliposome antigen particle platform in which recombinant SFTSV antigens comprising a polyhistidine tag are associated with cobalt-porphyrin-phospholipid-containing liposomes through cobalt-histidine coordination, thereby displaying the antigens on the surface of the liposomes. In some embodiments, the antigens comprise SFTSV Gn or Gc proteins, fragments, domains, or subdomains thereof, including Gn subdomain Ill-containing constructs that retain reactivitywith neutralizing antibodies and elicit SFTSV-neutralizing immune responses. The liposomes may further include one or more phospholipids, sterols, polyethylene gly col-lipids, adjuvants, or other lipid components, and the compositions may further comprise pharmaceutically acceptable carriers, buffers, stabilizers, cryoprotectants, or other excipients suitable for administration to a subject. The disclosure further provides methods of preparing such compositions and methods of administering the compositions to subjects to elicit antigenspecific immune responses, induce neutralizing antibodies, induce a subdomain III immune response, and inhibit, reduce, or prevent SFTSV infection or disease.
[0006] The present disclosure provides immunogenic compositions and vaccine compositions for inducing an immune response against Severe Fever with Thrombocytopenia Syndrome virus (SFTSV). In various aspects, the compositions comprise a plurality of liposomes or other nanostructures comprising a cobalt-porphyrin-phospholipid-containing monolayer or bilayer and one or more recombinant SFTSV antigens associated therewith. In some embodiments, the recombinant SFTSV antigen comprises an SFTSV glycoprotein, or an immunogenic fragment, domain, or subdomain thereof, including an SFTSV Gn or Gc antigen. In certain embodiments, the antigen comprises an SFTSV Gn antigen comprising subdomain III, including, without limitation, SD2 / 3, SD1 / 2 / 3, G23, or G constructs. In some embodiments, the SFTSV antigen comprises a polyhistidine tag that facilitates association of the antigen with the cobalt-porphyrin-phospholipid-containing liposome through cobalthistidine coordination, thereby displaying at least a portion of the antigen on the surface of the liposome.
[0007] In some aspects, the present disclosure provides spontaneous nanoliposome antigen particle (SNAP) vaccine compositions in which a polyhistidine-tagged SFTSV antigen is non-covalently coupled to a CoPoP-containing liposome. The polyhistidine tag may comprise, for example, four or more consecutive histidine residues, such as 4, 5, 6, or 7 histidine residues, and may be positioned at the N-terminus or C-terminus of the antigen. In certain embodiments, the antigen is a C-terminally His-tagged SFTSV Gn construct comprising subdomains I, II, and III. In some embodiments, the liposome-bound antigen retains conformational epitopes recognized by neutralizing antibodies and is capable of eliciting SFTSV-neutralizing antibodies following administration to a subject.
[0008] In various examples, the liposomes comprise one or more phospholipids, sterols, polyethylene gly col-lipids, porphyrin-phospholipid conjugates, cobalt-porphyrinphospholipid conjugates, or combinations thereof. In some embodiments, the cobalt-porphyrin-phospholipid conjugate comprises CoPoP. In certain embodiments, the liposomesfurther comprise one or more adjuvants, including lipid-phase adjuvants. Suitable adjuvants include, without limitation, monophosphoryl lipid A (MPLA), phosphorylated hexaacyl disaccharide (PHAD), PHAD-3D6A, QS-21, saponin-based adjuvants, TLR agonists, or combinations thereof. In particular embodiments, the liposomes comprise CoPoP, PHAD or PHAD-3D6A, and QS-21. The vaccine compositions may further comprise a pharmaceutically acceptable carrier, buffer, stabilizer, cryoprotectant, saccharide, excipient, or combination thereof.
[0009] In some aspects, the present disclosure provides methods of making an immunogenic composition or vaccine composition by contacting a polyhistidine-tagged SFTSV antigen with a CoPoP-containing liposome under conditions sufficient for the antigen to associate with the liposome. In some embodiments, the association occurs without covalent conjugation chemistry and without requiring reactive coupling groups, catalysts, or nonnatural amino acids. In certain embodiments, the resulting liposome-antigen complex presents the SFTSV antigen on the surface of the liposome and forms a stable particulate vaccine composition suitable for administration to a subject.
[0010] The present disclosure further provides methods of using the disclosed compositions to elicit an immune response in a subject. In some embodiments, the method comprises administering to the subject an effective amount of a vaccine composition described herein. The immune response may comprise production of antigen-specific antibodies, production of SFTSV-neutralizing antibodies, induction of a subdomain III immune response, or a combination thereof. In certain embodiments, administration of the vaccine composition inhibits, reduces, or prevents SFTSV infection or Severe Fever with Thrombocytopenia Syndrome in the subject. The compositions may be administered by any suitable route, including, without limitation, intramuscular, subcutaneous, intradermal, mucosal, intraperitoneal, intravenous, oral, or topical administration, and may be administered as a single dose or as multiple doses, including one or more booster doses.
[0011] In various examples, the amount of SFTSV antigen administered is sufficient to induce an immune response against SFTSV. For example, in some embodiments, the vaccine composition comprises an antigen dose suitable for human administration, including about 0.1 pg to about 5000 pg of total antigen, about 1 pg to about 2.0 mg, about 100 pg to about 1 mg, about 200 pg to about 800 pg, about 250 pg to about 750 pg, or about 500 pg. In some embodiments, the vaccine composition is formulated for storage stability, including with one or more buffers or stabilizing agents such as sucrose, mannitol, HEPES buffer, or combinations thereof.BRIEF DESCRIPTION OF THE FIGURES
[0012] For a fuller understanding of the nature and objects of the disclosure, reference should be made to the following detailed description taken in conjunction with the accompanying figures.
[0013] FIG. 1. Concept of the SGn-SNAP vaccine. A recombinant, his-tagged SFTSV Gn antigen is displayed on the surface of SNAP liposomes that also contain lipid-phase QS-21 and MPLA adjuvants, yielding the SGn-SNAP vaccine candidate.
[0014] FIG. 2. Pilot expression study of recombinant his-tagged Gn antigens comprising Gn subdomain III and other subdomains. A) Structure of Gn as reported by Wu et al. The neutralizing antibody MAb 4-5 targets subdomain III. B) Structure of antigens for preliminary expression analysis. C) Yields and SDS-PAGE purity after expressing the various constructs at pilot scale in CHO cells. Reducing (R) and non-reducing (NR) conditions shown. Two different secretion signals were placed at the N terminus of the construct and assessed to compare yields.
[0015] FIG. 3. SFTSV Gn SD2 / 3 and SD 1 / 2 / 3 rapidly display on the surface of immunogenic CPQ liposomes, but only SD 1 / 2 / 3 is reactive with MAb 4-5. A) His-tagged SD proteins were incubated for 3 hours with PBS or SNAP liposomes containing CoPoP, PHAD, and QS-21 (CPQ). Next, solutions were mixed with Ni-NTA purification beads, and the supernatant (S) and beads (B) were separated and assessed with SDS-PAGE. The his-tagged proteins bound to the Ni-NTA beads in PBS, but not after incubation with CPQ liposomes, indicating successful conversion from soluble to liposome-bound format. B) Size of antigens displayed on CPQ liposomes. C) Slot blot reactivity of proteins with the MAb 4-5 neutralizing antibody.
[0016] FIG. 4. SD 1 / 2 / 3 biochemical stability when stored at room temperature for 28 days, either displayed on immunogenic CPQ liposomes (A) or in PBS (B). Protein was stored at room temperature and sampled at various time points and frozen in SDS-PAGE loading buffer prior to running the gel after one month. Variability in migration of SD 1 / 2 / 3 displayed on CPQ in A could be due to issues with disruption of the antigen-liposome complex.
[0017] FIG. 5. SGn-SNAP elicits SFTSV neutralizing antibodies. Outbred female ICR mice were immunized intramuscularly with 2 pg of Gn antigen (either SD2 / 3 or SD / 1 / 23) admixed with CPQ, 2HPQ, or Alum on day 0 and day 14. Sera was collected on day 28. A) IgG titers for SD2 / 3 or SD1 / 2 / 3 antigens. B) HB29 neutralization titer and C) YG1 neutralization titer.
[0018] FIG. 6. The SFTSV full Gn head containing subdomain III expresses highly in various his-tagged formats compared to other subdomain III constructs. A) Schematic representation of SFTSV Gn protein and the recombinant constructs assessed. B) Yields of indicated constructs in CHO cells. C) SDS-PAGE of purified proteins. D) SFTS Gn head (abbreviated as “G”) constructs with varying his-tag orientations and lengths. The sequences in this figure are G-4H (SEQ ID NO:3), G-5H (SEQ ID NO:4), G-6H (SEQ ID NO:5), G-7H (SEQ ID NO:7), 6H-G (SEQ ID NO:8), and 7H-G (SEQ ID NOV). E) Yields of protein purification. F) SDS-PAGE and G) Western blot of G constructs.
[0019] FIG. 7. His-tagged G binds to CoPoP liposomes and his-tag orientation impacts reactivity with a neutralizing antibody. A) Nickel-NTA assay showing that the indicated G and G23 constructs bind to CoPoP / PHAD / QS-21 liposomes as reflected by low protein presence in the Ni-NTA beads (“B”) fraction compared to the supernatant “S” fraction following incubation of protein with liposomes, but not PBS. B) Particle size and C) poly dispersity. D) Reactivity with neutralizing antibody MAb4-5 for G and G23. E) Reactivity with MAb4-5 for G with varying his-tag orientations and lengths. F) Loss of MAb4-5 reactivity in liposome bound format, based on slot blot quantification. Data show mean + / - std. dev. for n=3.
[0020] FIG. 8. Stability of G-6H in storage. A) SDS-PAGE stability of G-6H in indicated storage conditions either in soluble or liposome bound format. B) Particle size prior and after storage at indicated temperatures.
[0021] FIG. 9. SGn-SNAP elicits SFTSV neutralizing antibodies. Outbred female ICR mice were immunized intramuscularly with 2 pg of G or G23 antigen admixed with CPQ, 2HPQ, or Alum on day 0 and day 14. Sera was collected on day 28. A) IgG titers for G23-6H or G-6H antigens. B) HB29 neutralization titer and C) YG1 neutralization titer.
[0022] FIG. 10. Outbred female ICR mice were immunized intramuscularly with 2 pg of G antigen with indicated his-tag admixed with CPQ, 2HPQ, or Alum on day 0 and day 14. Sera was collected on day 28. A) IgG titers for G23-6H or g-6h antigens. B) HB29 neutralization titer and C) YG1 neutralization titer.
[0023] FIG. 11. Loss in reactivity with MAb 4-5 at elevated storage temperatures. Gn-H6 bound to CoPoP liposomes was stored in indicated buffers at 37C for two days prior to probing reactivity via slot blot with MAb 4-5. Control liposome samples were maintained in PBS at4C.DETAILED DESCRIPTION OF THE DISCLOSURE
[0024] Although claimed subject matter will be described in terms of certain examples, other examples, including examples that do not provide all of the benefits and features set forth herein, are also within the scope of this disclosure. Various structural, logical, process step, and electronic changes may be made without departing from the scope of the disclosure.
[0025] As used herein, unless otherwise indicated, “about”, “substantially”, or “the like”, when used in connection with a measurable variable (such as, for example, a parameter, an amount, a temporal duration, or the like) or a list of alternatives, is meant to encompass variations of and from the specified value including, but not limited to, those within experimental error (which can be determined by, e.g., a given data set, an art accepted standard, etc. and / or with, e.g., a given confidence interval (e.g. 90%, 95%, or more confidence interval from the mean), such as, for example, variations of + / - 10% or less, + / -5% or less, + / -1% or less, and + / -0.1% or less of and from the specified value), insofar such variations in a variable and / or variations in the alternatives are appropriate to perform in the instant disclosure. As used herein, the term “about” may mean that the amount or value in question is the exact value or a value that provides equivalent results or effects as recited in the claims or taught herein. That is, it is understood that amounts, sizes, compositions, parameters, and other quantities and characteristics are not and need not be exact but may be approximate and / or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error, or the like, or other factors known to those of skill in the art such that equivalent results or effects are obtained. In general, an amount, size, composition, parameter, or other quantity or characteristic, or alternative is “about” or “the like,” whether or not expressly stated to be such. It is understood that where “about,” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.
[0026] Ranges of values are disclosed herein. The ranges set out a lower limit value and an upper limit value. Unless otherwise stated, the ranges include the lower limit value, the upper limit value, and all values between the lower limit value and the upper limit value, including, but not limited to, all values to the magnitude of the smallest value (either the lower limit value or the upper limit value) of a range. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within thatrange as if each numerical value and sub-range is explicitly recited. To illustrate, a numerical range of “0.1% to 5%” should be interpreted to include not only the explicitly recited values of 0.1% to 5%, but also, unless otherwise stated, include individual values (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5% to 1.1%; 0.5% to 2.4%; 0.5% to 3.2%, and 0.5% to 4.4%, and other possible sub-ranges) within the indicated range. It is also understood (as presented above) that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Ranges can be expressed herein as from “about” one particular value, and / or to “about” another particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about, it will be understood that the particular value forms a further disclosure. For example, if the value “about 10” is disclosed, then “10” is also disclosed.
[0027] The articles “a” and “an” are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0028] As used herein, unless otherwise stated or indicated, “s” refers to second(s), “min” refers to minute(s), and “h” refers to hour(s).
[0029] As used herein, unless otherwise stated, the term “group” refers to a chemical entity that is monovalent (i.e., has one terminus that can be covalently bonded to other chemical species), divalent, or polyvalent (i.e., has two or more termini that can be covalently bonded to other chemical species). The term “group” also includes radicals (e.g., monovalent and multivalent, such as, for example, divalent radicals, trivalent radicals, and the like).Illustrative examples of groups include:
[0030] As used herein, “phospholipid” is a lipid having a hydrophilic head group having a phosphate group connected via a glycerol backbone to a hydrophobic lipid tail. The phospholipid comprises an acyl side chain of 6 to 22 carbons, including all integer number of carbons and ranges therebetween. In certain examples, the phospholipid in the porphyrin conjugate is l-palmitoyl-2-hydroxy-sn-glycero-3 -phosphocholine. The phospholipid of the porphyrin conjugate may comprise, or consist essentially of phosphatidylcholine, phosphatidylethanoloamine, phosphatidylserine and / or phosphatidylinositol.
[0031] As used herein, the term “therapeutically effective amount” or “therapeutically or prophylactically effective amount” refers to an amount of a composition, antigen, liposome, vaccine composition, or other active agent described herein that, when administered to a subject, is sufficient to achieve a desired therapeutic, prophylactic, immunogenic, or biological effect. Such effects may include, without limitation, eliciting or enhancing an immune response, inducing production of antibodies, including neutralizing antibodies, inducing a subdomain III immune response, reducing the likelihood, severity, duration, or progression of Severe Fever with Thrombocytopenia Syndrome (SFTS), reducing viral infection, replication, transmission, or disease symptoms associated with SFTSV, or partially or completely inhibiting SFTS in the subject. A therapeutically effective amount may vary depending on factors including the particular composition administered, the antigen or antigens included therein, the presence and identity of any adjuvant, the route of administration, the dosing regimen, the age, weight, health, and species of the subject, and the desired immune or clinical outcome. In some embodiments, a therapeutically effective amount includes an amount sufficient to elicit SFTSV-neutralizing antibodies following one or more administrations of a vaccine composition described herein. In some embodiments, a therapeutically effective amount of an antigen, such as an SFTSV Gn or Gc antigen or fragment thereof, may be in the range of about 0.1 pg to about 5000 pg for human administration, including, for example, about 1 pg to about 2.0 mg, about 100 pg to about 1 mg, about 200 pg to about 800 pg, about 250 pg to about 750 pg, or about 500 pg. A therapeutically effective amount may be administered as a single dose or as multiple doses, including one or more booster doses.
[0032] Provided are liposomes and compositions comprising the liposomes. The liposomes may comprise one or more cobalt porphyrins suitable for covalently binding polyhistidine-tagged molecules, such that at least part of the polyhistidine tag resides within the bilayer and the tagged molecule is presented on the surface of the bilayer.
[0033] The present disclosure relates generally to immunogenic and vaccine compositions for eliciting immune responses against Severe Fever with Thrombocytopenia Syndrome virus (SFTSV), including compositions comprising recombinant SFTSV glycoprotein antigens displayed on liposomes or other nanostructures. In particular, the disclosure provides liposomal vaccine compositions comprising cobalt-porphyrinphospholipid (CoPoP)-containing bilayers capable of associating with polyhistidine-tagged SFTSV antigens, including Gn antigens or fragments thereof, through cobalt-histidine coordination, thereby presenting the antigens on the surface of the liposomes. In variousembodiments, the SFTSV antigens comprise one or more domains or subdomains of SFTSV Gn, including subdomain Ill-containing constructs such as SD2 / 3, SD1 / 2 / 3, G23, or G antigens, optionally comprising N-terminal or C-terminal polyhistidine tags. The disclosed compositions may further comprise one or more adjuvants, including lipid-phase adjuvants such as PHAD, MPLA, QS-21, or combinations thereof, and may be formulated with pharmaceutically acceptable carriers, buffers, stabilizers, saccharides, or other excipients. The disclosure also provides methods of making and using such compositions, including methods of eliciting an immune response, inducing antibodies including neutralizing antibodies, inducing a subdomain III immune response, and inhibiting, reducing, or preventing SFTSV infection or Severe Fever with Thrombocytopenia Syndrome in a subject. In certain embodiments, the disclosed SNAP-based vaccine compositions provide stable, particulate, and immunogenic presentation of SFTSV antigens and may be administered in one or more doses, including booster doses, by suitable routes of administration.
[0034] Some or all of the cobalt porphyrins in the monolayer or bilayer can non-covalently bind polyhistidine-tagged molecules, such that at least part of the polyhistidine tag resides within the bilayer and the tagged molecule is presented on the surface of the bilayer. In the present bilayers or monolayers, it is considered that one or more histidine residues in the polyhistidine tag are coordinated to the cobalt metal core within the bilayer, thereby providing stability to the structure. The histidine residues of a polyhistidine tag may be coordinated to the cobalt metal in the core of the porphyrin in the membrane. The entire histidine tag may reside within the bilayer. A porphyrin phospholipid conjugate which has cobalt metal conjugated thereto is referred to herein as CoPoP. Liposomes wherein the bilayer comprises CoPoP are referred to herein as CoPoP liposomes. The CoPoP liposomes can be functionalized with histidine tagged molecules. The term “His-tagged molecules” as used herein means molecules — such as, for example, peptides, polypeptides, or proteins — which have a histidine tail. For example, a peptide with a histidine tail is a His-tagged molecule. Such His-tag containing CoPoP liposomes are referred to herein as His-tagged CoPoP liposomes or His-tagged CoPoP. The His-tag may have 2, 3, 4, 5, or 6 histidine residues.
[0035] The CoPoP monolayers or bilayers functionalized with His-tagged presentation molecules of the present disclosure provide a platform for presentation of various molecules of interest in the circulation or for delivery to desired locations or for generation of specific immune responses to those His-tagged molecules. These molecules are referred to herein as presentation molecules (PMs). Structures containing His-tagged CoPoPbilayers, which have PMs attached to the histidine tag exhibit desirable stability. The his-tagged molecules are non-covalently attached to (coordinated to) the CoPoP and can be prepared by an incubation process. Therefore, the process does not need removal of reactive moieties - such as maleimide and the like — or exogenous catalysts or non-natural amino acids that are used in other types of conjugation chemistries.
[0036] The cobalt-porphyrin may be in a bilayer in self-assembling liposomes enclosing therewithin an aqueous compartment. Alternatively, it may be in a single layer or bilayer coating that coats other nanoparticles. Cobalt-porphyrin phospholipid (CoPoP) behaves like a conventional lipid with respect to its amphipathic nature. Therefore, monolayers or bilayers comprising CoPoP can be used for coating of nanoparticles by methods that are known to those skilled in the art. In one example, the bilayer or monolayer of the present disclosure may be present on other nanoparticles, such as, for example, in the form of a coating. In one example, the bilayer or monolayer containing cobalt-porphyrin (e.g., cobalt porphyrin-phospholipid) is present as a coating on gold or silica nanoparticles, or other nanoparticles with a hydrophilic surface. In one example, the coating may be in the form of monolayers. In one example the monolayer or bilayer containing cobalt-porphyrin (e.g., cobalt porphyrin-phospholipid) is present as a coating on hydrophobic surfaces such as carbon nanotubes. In one example, the monolayers may form micelles surrounding one or more hydrophobic molecules.
[0037] This disclosure provides a nanostructure comprising a monolayer or a bilayer, wherein the monolayer or bilayer comprises: i) optionally, phospholipids and ii) porphyrin which has cobalt coordinated thereto forming cobalt-porphyrin. Optionally, the nanostructure also has one or more polyhistidine-tagged presentation molecule. At least a portion of the polyhistidine tag resides in the hydrophobic portion of the monolayer or the bilayer and one or more histidine residues of the polyhistidine tag are coordinated to the cobalt in the cobalt-porphyrin. At least a portion of the polyhistidine-tagged presentation molecule is exposed to the outside of the nanostructure. The nanostructure can be in the form of a liposome that encloses an aqueous compartment. However, the nanostructure may also coat a hydrophilic or hydrophobic material such as a gold or silica nanoparticle. The cobalt porphyrin may be conjugated to a phospholipid to form a cobalt porphyrin-phospholipid conjugate. The cobalt porphyrin can make up from 1 to 100 mol % of the monolayer or the bilayer, including 0.1 mol% values and ranges therebetween. For example, the cobalt porphyrin can make up from 1 to 20 mole %, or from 5 to 10 mol% of the monolayer or the bilayer. If the cobalt porphyrin makes up 100% of the monolayer or the bilayer, then there are no phospholipids present thatare not conjugated to cobalt porphyrin. The bilayer or the monolayer can also comprise sterol and / or polyethylene glycol. The sterol can be cholesterol.
[0038] The peptides described herein may include histidine residues that enable coordination with cobalt present in the CoPoP component of the liposomes. This cobalthistidine coordination may allow for spontaneous nanoparticle antigen particle (SNAP) formation. SNAP formation refers to the spontaneous and stable display of histidine-tagged antigens on the surface of CoPoP-containing liposomes through metal chelation. In some examples, the histidine-cobalt chelation preserves epitope integrity while providing stable antigen presentation on the liposome surface. The number of histidine residues in the polyhistidine-tag (polyHis-tag) in the monolayer or bilayer can be from 3 to 15, including all integer values and ranges therebetween. For example, the number of histidine residues can be 4, 5, 6, or 7. The polyHis-tag may be on the N- or C-terminus of the peptide fragment or antigen fragment.
[0039] The SNAP approach may offer advantages. The cobalt-histidine coordination may enable rapid and efficient peptide binding to the liposome surface without covalent conjugation chemistry. In some examples, the peptide antigens retain their native conformation and epitope structure following association with the liposomes. The liposomal formulations may maintain consistent particle size and low poly dispersity, indicating minimal aggregation following peptide association.
[0040] The liposomes may be spherical or non- spherical. The size of the liposomes can be from 50 to 1000 nm or more. In one example, the liposomes have a size (e.g., a longest dimension such as, for example, a diameter) of 50 to 1000 nm, including all integer nm values and ranges therebetween. For example, the size may be from 50 to 200 nm or from 20 to 1000 nm. If the liposomes are not spherical, the longest dimension can be from 50 to 1000 nm. These dimensions can be achieved while preserving the nanostructure width of the monolayer of the bilayer. The liposomes can carry cargo in the aqueous compartment. The cargo, or part thereof, can also, or alternatively, be incorporated in the monolayer or the bilayer.
[0041] In various examples, the present disclosure provides a liposome comprising: a monolayer or a bilayer, wherein the monolayer or bilayer comprises cobalt-porphyrin phospholipid conjugate, optionally phospholipids that are not conjugated to cobalt porphyrin, and a polyhistidine-tagged presentation molecule, wherein at least a portion of the polyhistidine tag resides in the hydrophobic portion of the monolayer or the bilayer and one or more histidine residues of the polyhistidine tag are coordinated to the cobalt in the cobalt-porphyrin phospholipid conjugates. At least a portion of the polyhistidine-tagged presentation molecule is exposed to the outside of the nanostructure. The nanostructure, such as a liposome, can enclose an aqueous compartment. The monolayer or the bilayer need not contain any phospholipids that are not conjugated to cobalt porphyrin and in this case only has cobalt porphyrin phospholipid conjugates. Cargo can be present in the aqueous compartment. The cargo need not reside exclusive in the aqueous compartment and a part thereof can reside in the monolayer or the bilayer.
[0042] Liposomes comprising His-tagged polypeptides and CoPoP compositions exhibit high serum-stability with respect to binding of the His-tagged polypeptide to the liposome. In one example, when incubated with serum (such as diluted serum) at room temperature, more than 60% of the His-tagged peptide remains bound to the CoPoP -containing bilayer after 24 hours incubation. In one example, more than 85% of the His-tagged peptide remains bound to the CoPoP layer after incubation with serum for 24 hours.
[0043] The CoPoP liposomes or the His-tagged CoPoP liposomes can be loaded with cargo — which typically resides in the aqueous compartment but may reside entirely or partially embedded in the bilayer — if it is hydrophobic or has a hydrophobic component. In addition to having presentation molecules on the surface, these structures can be used to load cargo in the aqueous compartment within the structures, or in the bilayer.
[0044] The cobalt-porphyrin of the monolayers or bilayers is a porphyrin having a cobalt (Co) cation conjugated to the porphyrin. The porphyrin can be conjugated to a phospholipid (referred to herein as a cobalt porphyrin-phospholipid or cobalt porphyrinphospholipid conjugate).
[0045] In one example, the PoP is pyropheophorbide-phospholipid. The structure of pyropheophorbide-phospholipid is shown below:
[0046] In one example, the layer (monolayer or bilayer) has only CoPoP which has his-tagged presentation molecules embedded therein. In this example, the only phospholipid in the layer is CoPoP (i.e., CoPoP is 100 mol %). In one example, the layer (monolayer or bilayer) has only CoPoP and porphyrin conjugated phospholipids (PoP), wherein CoPoP has histidines embedded therein, with the histidine residues having a peptide or other presentation molecules attached thereto. In certain examples, there are no other phospholipids, but the layer (monolayer or bilayer) may optionally contain sterols and / or PEG-lipid.
[0047] In one example, in addition to the CoPoP, the bilayer or monolayer also has phospholipids which are not conjugated to porphyrin and therefore, not coordinated with Co. Such phospholipids may be referred to herein as “additional phospholipids.” The bilayer or monolayer may also comprise sterol and PEG-lipid. In one example, the bilayer or monolayer consists essentially of, or consists of CoPoP, phospholipids that are not conjugated to porphyrins, and optionally sterol and / or PEG, wherein the PEG may be conjugated to lipid. In one example, the only metal-PoP in the bilayer is CoPoP, which has his-tagged presentation molecules embedded therein. In one example, the only metal or metal ion in the bilayer found in non-trace amounts is Co.
[0048] In one example, the bilayer of the liposomes comprises CoPoP and PoP. In addition to the CoPoP and the PoP, the bilayer can have additional phospholipids. The bilayer or monolayer may further comprise sterol and / or PEG. The PEG may be conjugated to lipid. In one example, the bilayer consists essentially of, or consists of CoPoP, PoP, additional phospholipids, and optionally sterol and / or PEG, wherein the PEG may be conjugated to lipid. In one example, the only metal-PoP in the bilayer is CoPoP. In one example, the only metal in the bilayer is Co.
[0049] In one example, the CoPoP is present in the nanoparticles from 0.1 to 20 mol % with the remainder 99.9 to 80 mol % being made up by additional lipids, with the percent being of the entire bilayer lipids. For example, the combination of CoPoP can be present from 0.1 to 10 mol %, sterol can be present from 0.1 to 50 mol %, optionally, attenuated lipid A derivatives such as monophosphoryl lipid A or 3 -deacylated monophosphoryl lipid A or a related analog that is a toll-like-receptor 4 (TLR4) lipid agonist can be present from 0 to 20 mol % or 0.1 to 20 mol %, and the remainder can be made up by additional phospholipids. The phospholipids are DOPC, DSPC, DMPC or combinations thereof, and sterol, if present, can be cholesterol. In various examples, the ratio range is 20:5:1 to 20:5:5 (DOPC : sterol (e.g., cholesterol) : CoPoP).
[0050] In one example, the combination of CoPoP and PoP may be present in the nanoparticles from 0.1 to 20 mol % with the remaining 99.9 to 80 mol% being made up by additional phospholipids. For example, the combination of CoPoP and PoP can be present from 0.1 to 10 mol %, sterol can be present from 0 to 50 mol % or 0.1 to 50 mol%, and the remainder can be made up by phospholipids. The phospholipids can be DOPC, DSPC, DMPC or combinations thereof and sterol, if present, can be cholesterol.
[0051] The liposomal vaccine compositions described herein may comprise a phospholipid component, cholesterol, an adjuvant, and cobalt-porphyrin-phospholipid (CoPoP). In some examples, the phospholipid component comprises 1,2-dioleoyl-sn-glycero-3 -phosphocholine (DOPC). DOPC is a phosphatidylcholine with two oleoyl fatty acid chains that may form the primary structural component of the liposome bilayer.
[0052] In certain examples, the porphyrin is conjugated to the glycerol group on the phospholipid by a carbon chain linker of 1 to 20 carbons, including all integer number of carbons therebetween.
[0053] In various examples, in addition to the porphyrin conjugates disclosed herein, the bilayer of the liposomes also comprises other phospholipids. The fatty acid chains of these phospholipids may contain a suitable number of carbon atoms to form a bilayer. For example, the fatty acid chain may contain 12, 14, 16, 18 or 20 carbon atoms. In different examples the bilayer comprises phosphatidylcholine, phosphatidylethanoloamine, phosphatidyl serine and / or phosphatidylinositol.
[0054] The present bilayers and monolayers may also comprise sterols. The sterols may be animal sterols or plant sterols. Examples of sterols include cholesterol, sitosterol, stigmasterol, and cholesterol. In examples, cholesterol may be from 0 mol % to 50 mol %, or 0.1 to 50 mol %. In other examples, cholesterol may be present from 1 to 50 mol%, 5 to 45 mol%, 10 to 30 mol%.
[0055] The vaccine composition may further comprise various adjuvants. The adjuvant can be administered as a separate component in the compositions, or it can be incorporated into the liposome. Examples of adjuvants include complete monophosphoryl lipid A (MPLA), phosphorylated hexaacyl disaccharide (PHAD), Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl (PHAD-3D6A), QS21, CL401, saponin, and combinations thereof. Other carriers like wetting agents, stabilizers, emulsifiers, fillers, and the like may also be used. MPLA can be used in the present compositions and methods, including PHAD, PHAD-504, and PHAD-3D6A or other related forms of lipid TLR4 agonist.
[0056] An adjuvant can be used as a 0.001 to 50 wt % solution in phosphate buffered saline, and the antigen is present in the order of micrograms to milligrams, such as about 0.0001 to about 5 wt %, such as about 0.0001 to about 1 wt %, or such as about 0.0001 to about 0.05 wt %. The antigen can be present in an amount in the order of micrograms to milligrams, or, about 0.001 to about 20 wt %, such as about 0.01 to about 10 wt %, or about 0.05 to about 5 wt %.
[0057] The liposomes of the present disclosure (without the His-tagged molecules) can be substantially spherical and have a size (e.g., a longest dimension such as, for example, a diameter) of 30 nm to 250 nm, including all integers to the nm and ranges therebetween. In one example, the size of the liposomes is from 100-175 nm. In one example, at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% of the liposomes in the composition have a size of from 30 to 250 nm or from 100 to 175 nm. The liposomes or nanostructures can be more than 200 nm. In one example, the nanostructures are more than 1000 nm. In one example, the nanostructures are from 200 to 1000 nm. The liposomes or nanostructures may be spherical or non-spherical. In one example, the largest dimensions of the nanostructure are less than 200 nm, while preserving the nanostructure width of the monolayer or bilayer. In one example, the size of the nanostructure exceeds 200 nm in some dimensions, while preserving the nanostructure width of the monolayer or bilayer. In one example, the size of the nanostructure exceeds 1000 nm in some dimensions, while preserving the nanostructure width of the monolayer or bilayer.
[0058] The structures formed by the layers of the present disclosure are serum stable. For example, in vitro, the His-tag binding stability to the CoPoP bilayers is stable when incubated in 50% bovine serum at room temperature for 24 hours. Thus, these structures can be stable under serum or concentrated or diluted serum conditions.
[0059] The liposomes may have various peptide fragments or protein fragments chelated thereto. In various examples, the protein fragment or peptide fragment is a glycoprotein. The protein fragment or peptide fragment may be a domain of a larger protein or peptide. In various examples, the protein is SFTSV, which comprises two envelope glycoproteins, Gc and Gn, each of which may comprise multiple domains. For example, the protein fragment or peptide fragment comprise SD 1 / 2 / 3 or SD2 / 3. In various examples, both are displayed on the surface of the liposome. Examples of sequences are found in Table 1. In various examples, the attached sequence may have at least 80% (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater than 99%) identity to any one of the sequences in Table 1.
[0060] In various examples, the peptide or protein fragments may further comprise a secretion signal sequence. In various examples, the secretion signal sequence is a AZCLD or TEMPI secretion signal. In various examples, the secretion signal sequence is MGWSCIILFLVATATGVHS (SEQ ID NO: 10) or MAPFASLASGILLLLSLITSSKA (SEQ ID NO: 11). In various examples, the secretion signal sequence may be conjugated to the N-terminus of the peptide or protein fragment (e.g., SD1 / 2 / 3 or SD2 / 3). In various examples, the secretion signal sequence may further comprise a histidine tag. The histidine tag may comprise 2, 3, 4, 5, 6, or 7 histidine residues. In various examples, the histidine tag is conjugated to the N- or C-terminus of the secretion signal sequence. In various examples the sequence is MAPFASLASGILLLLSLITSSKA-HHHHHH (SEQ ID NO: 12) or MAPFASLASGILLLLSLITSSKA-HHHHHHH (SEQ ID NO: 13). In various examples, the secretion signal sequence has at least 80% (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater than 99%) identity to any one of SEQ ID NO: 10 or SEQ ID NO: 11. The secretion signal sequence may be referred to herein as the signal peptide, secretion signal, or secretion peptide.
[0061] Table 1. Amino acid sequence of SFTS constructs used, with secretion signal in bold, domain 2 shown in italics and domain 3 in underline.Construct Sequence SEQ name IDNO:MGWS C 11 LFLVATATGVHSG23-6H GDVACQPMTPIPEETFLELKSFSQSEFPDICKIDGIVFNQCEGESLPQPSD1 / 2 FDVAWMDVGHSHKI IMREHKTKWVQESS SKDFVCYKEGTGPCSESEEKA 1 (AZCLD) CKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWS YGGTR VRPKCYGFSRMMATLEVN-titititititiMAPFASLASGILLLLSLITSSKAG23-6H GDVACQPMTPIPEETFLELKSFSQSEFPDICKIDGIVFNQCEGESLPQPSD1 / 2 FDVAWMDVGHSHKI IMREHKTKWVQES SSKDFVCYKEGTGPCSESEEKA 2 (TIMP1) CKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWSYGGTR VRPKCYGFSRMMATLEVN-titititititiMAPFASLASGILLLLSLITSSKA DSGPIICAGPIHSNKSAGIPHLLGYSEKICQIDRLIHVSSWLRNHSQFQ GYVGQRGGRSQVSYYPAENSYSRWSGLLSPCDADWLGMLWKKAKESDMG-4HIVPGPSYKGKVFFERPTFDGYVGWGCGSGKSRTESGELCSSDSGTSSGL SD 1 / 2 / 3 3LPSDRVLWIGDVACQPMTPIPEETFLELKSFSQSEFPDICKIDGIVFNQ(TIMP1) CEGESLPQPFDVAWMDVGHSHKIIMREHKTKWVQESSSKDFVCYKEGTG PCSESEEKACKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWS YGGTRVRPKCYGFSRMMA TLE VN- HHHHMAPFASLASGILLLLSLITSSKAG-5H DSGPIICAGPIHSNKSAGIPHLLGYSEKICQIDRLIHVSSWLRNHSQFQSD 1 / 2 / 3 GYVGQRGGRSQVSYYPAENSYSRWSGLLSPCDADWLGMLWKKAKESDM 4 (TIMP1) IVPGPSYKGKVFFERPTFDGYVGWGCGSGKSRTESGELCSSDSGTSSGLLPSDRVLWIGDVACQPMTPIPEETFLELKSFSQSEFPDICKIDGIVFNQCEGESLPQPFDVAWMDVGHSHKTTMREHKTKWVQESSSKEFVCYKEGTG PCSESEEKACKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWS YGGTRVRPKCYGFSPMMA TLE VN- HHHHHMAPFASLASGILLLLSLITSSKA DSGPIICAGPIHSNKSAGIPHLLGYSEKICQIDRLIHVSSWLRNHSQFQ GYVGQRGGRSQVSYYPAENSYSRWSGLLSPCDADWLGMLWKKAKESDMG-6HIVPGPSYKGKVFFERPTFDGYVGWGCGSGKSRTESGELCSSDSGTSSGL SD 1 / 2 / 3 5LPSDRVLWIGDVACQPMTPIPEETFLELKSFSQSEFPDICKIDGIVFNQ(TIMP1) CEGESLPQPFDVAWMDVGHSHKTTMREHKTKWVQESSSKDFVCYKEGTG PCSESEEKACKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWS YGGTRVRPKCYGFSPMMA TLE VN- HHHHHHMGWS C 11 LFLVATATGVHS DSGPIICAGPIHSNKSAGIPHLLGYSEKICQIDRLIHVSSWLRNHSQFQ GYVGQRGGRSQVSYYPAENSYSRWSGLLSPCDADWLGMLWKKAKESDMG-6HIVPGPSYKGKVFFERPTFDGYVGWGCGSGKSRTESGELCSSDSGTSSGL SD 1 / 2 / 3 6LPSDRVLWIGDVACQPMTPTPEETFLELKSFSQSEFPDTCKTDGTVFNQ(AZCLD) CEGESLPQPFDVAWMDVGHSHKTTMREHKTKWVQESSSKDFVCYKEGTG PCSESEEKACKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWS YGGTRVRPKCYGFSPMMA TLEVN- HHHHHHMAPFASLASGILLLLSLITSSKA DSGPIICAGPIHSNKSAGIPHLLGYSEKICQIDRLIHVSSWLRNHSQFQ GYVGQRGGRSQVSYYPAENSYSRWSGLLSPCDADWLGMLWKKAKESDMG-7HIVPGPSYKGKVFFERPTFDGYVGWGCGSGKSRTESGELCSSDSGTSSGL SD 1 / 2 / 3 7LPSDRVLWIGDVACQPMTPTPEETFLELKSFSQSEFPDTCKTDGTVFNQ(TIMP1) CEGESLPQPFDVAWMDVGHSHKTTMREHKTKWVQESSSKDFVCYKEGTG PCSESEEKACKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWS YGGTR VRPKC YGFSRMMA TLE VN- HHHHHHHMAPFASLASGILLLLSLITSSKA-HHHHHH DSGPIICAGPIHSNKSAGIPHLLGYSEKICQIDRLIHVSSWLRNHSQFQ GYVGQRGGRSQVSYYPAENSYSRWSGLLSPCDADWLGMLWKKAKESDM6H-GIVPGPSYKGKVFFERPTFDGYVGWGCGSGKSRTESGELCSSDSGTSSGL SD 1 / 2 / 3 8LPSDRVLWIGDVACQPMTPTPEETFLELKSFSQSEFPDTCKTDGTVFNQ(TIMP1) CEGESLPQPFDVAWMDVGHSHKTTMREHKTKWVQESSSKDFVCYKEGTG PCSESEEKACKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWS YGGTRVRPKCYGFSPMMA TLEVN MAPFASLASGILLLLSLITSSKA-HHHHHHH DSGPIICAGPIHSNKSAGIPHLLGYSEKICQIDRLIHVSSWLRNHSQFQ GYVGQRGGRSQVSYYPAENSYSRWSGLLSPCDADWLGMLWKKAKESDM7H-GIVPGPSYKGKVFFERPTFDGYVGWGCGSGKSRTESGELCSSDSGTSSGL SD 1 / 2 / 3 9LPSDRVLWIGDVACQPMTPTPEETFLELKSFSQSEFPDTCKTDGTVFNQ(TIMP1) CEGESLPQPFDVAWMDVGHSHKTTMREHKTKWVQESSSKDFVCYKEGTG PCSESEEKACKTSGSCRGDMQFCKVAGCEHGEEASEAKCRCSLVHKPGE VWS YGGTRVRPKCYGFSPMMA TLEVN
[0062] In an aspect, the disclosure provides a composition comprising liposomes or other structures of the present disclosure or a mixture of different liposomes or other structures. The compositions can also comprise a sterile, suitable carrier for administration to subjects including humans, such as, for example, a physiological buffer such as sucrose, dextrose, saline, pH buffering (such as from pH 5 to 9, from pH 7 to 8, from pH 7.2 to 7.6, (e.g., 7.4)) element such as citrate or phosphate. In an example, the composition comprises atleast 0.1% (w / v) CoPoP liposomes or his-tagged-CoPoP liposomes or other structures. In various examples, the composition comprises from 0.1 to 100 mol% CoPoP liposomes or his-tagged CoPoP liposomes or other structures such as bilayer coated nanoparticles. In an example, the composition comprises from 0.1 to 99 mol% CoPoP liposomes having his-tagged presentation molecules associated therewith.
[0063] In an example, the peptides of the present disclosure are free of maleimide or succinimidyl ester reactive groups. In an example, the peptides of the present disclosure are free of covalent modification with any lipid moiety. In one example, the tagged molecule to be attached to the membrane does not have a non-natural amino acid.
[0064] In an aspect, the present disclosure provides a method of using a vaccine composition or immunogenic composition described herein, the method comprising administering to a subject an effective amount of a composition comprising one or more SFTSV antigens associated with a liposome or other nanostructure, thereby eliciting an immune response against SFTSV in the subject. The composition may comprise a recombinant SFTSV antigen having a polyhistidine tag associated with a liposome comprising a cobalt-porphyrin-phospholipid, such that the antigen is displayed on the surface of the liposome. The immune response may comprise an antigen-specific immune response, an antibody response, a neutralizing antibody response, a cellular immune response, or a combination thereof.
[0065] In some examples, the SFTSV antigen comprises an SFTSV Gn antigen, an SFTSV Gc antigen, or an immunogenic fragment, domain, or subdomain thereof. In some examples, the SFTSV antigen comprises a Gn subdomain Ill-containing antigen. In particular examples, the antigen comprises SD2 / 3, SD1 / 2 / 3, G23, G, or a variant thereof. In further examples, the antigen comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or greater sequence identity to any one of the SFTSV antigen sequences disclosed herein.
[0066] In some examples, the SFTSV antigen comprises a polyhistidine tag. The polyhistidine tag may comprise four or more consecutive histidine residues. In some examples, the polyhistidine tag comprises 4, 5, 6, 7, 8, 9, 10, or more histidine residues. The polyhistidine tag may be positioned at the N-terminus of the antigen, at the C-terminus of the antigen, or at an internal position within the antigen. In particular examples, the SFTSV antigen comprises a C-terminal polyhistidine tag. In other examples, the SFTSV antigen comprises an N-terminal polyhistidine tag.
[0067] In some examples, the composition administered to the subject comprises liposomes comprising cobalt-porphyrin-phospholipid. In particular examples, the cobalt-porphyrin-phospholipid comprises CoPoP. The polyhistidine-tagged SFTSV antigen may associate with the CoPoP-containing liposome through cobalt-histidine coordination. In some examples, at least a portion of the polyhistidine tag resides in or associates with the hydrophobic portion of the liposome bilayer, and at least a portion of the SFTSV antigen is exposed on the exterior surface of the liposome. In some examples, the antigen is associated with the liposome without covalent conjugation chemistry.
[0068] In some examples, the composition comprises one or more adjuvants. The one or more adjuvants may be associated with the liposome, incorporated into the liposome bilayer, mixed with the liposome, or separately administered. Suitable adjuvants include, without limitation, MPLA, PHAD, PHAD-3D6A, QS-21, saponin-based adjuvants, TLR agonists, or combinations thereof. In particular examples, the composition comprises CoPoP, PHAD orPHAD-3D6A, and QS-21.
[0069] In some examples, administration of the composition induces production of antibodies that bind to an SFTSV antigen. In some examples, administration induces production of antibodies that bind to SFTSV Gn. In further examples, administration induces production of antibodies that bind to a conformational epitope of SFTSV Gn. In still further examples, administration induces SFTSV-neutralizing antibodies. The neutralizing antibodies may neutralize a homologous SFTSV strain, a heterologous SFTSV strain, or both.
[0070] In some examples, administration of the composition induces an immune response against SFTSV Gn subdomain III. In particular examples, administration of a composition comprising a Gn subdomain Ill-containing antigen induces antibodies that recognize a neutralizing epitope within or dependent upon subdomain III. In some examples, the antigen is displayed on a CoPoP-containing liposome in a manner that preserves or presents one or more conformational epitopes of the antigen.
[0071] In some examples, the method reduces, inhibits, or prevents SFTSV infection in the subject. In some examples, the method reduces, inhibits, or prevents Severe Fever with Thrombocytopenia Syndrome. In further examples, the method reduces the severity, duration, progression, or incidence of one or more symptoms associated with SFTSV infection. In still further examples, the method reduces viral replication, viral load, viral spread, morbidity, or mortality associated with SFTSV infection.
[0072] The subject may be a human or a non-human animal. In some examples, the subject is a mammal. Non-human mammals may include, without limitation, mice, rats,rabbits, cats, dogs, pigs, bovines, other agricultural animals, companion animals, or service animals. In some examples, the subject is at risk of exposure to SFTSV. In other examples, the subject has been exposed to SFTSV or is suspected of having been exposed to SFTSV. In still other examples, the subject is in need of prophylactic or therapeutic immunization against SFTSV.
[0073] The composition may be administered by any suitable route. Suitable routes include, without limitation, intramuscular, subcutaneous, intradermal, intraperitoneal, intravenous, mucosal, oral, topical, or other parenteral administration. In some examples, the composition is administered intramuscularly. In other examples, the composition is administered mucosally or intranasally.
[0074] The composition may be administered once or more than once. In some examples, the method comprises administering a first dose of the composition to the subject. In further examples, the method comprises administering one or more booster doses after the first dose. The one or more booster doses may be administered at any suitable interval, including days, weeks, months, or years after a prior dose. The dosing schedule may be selected based on the subject, the antigen, the formulation, the route of administration, the desired immune response, or the durability of the immune response.
[0075] The amount of antigen administered may be any amount sufficient to elicit an immune response against SFTSV. In some examples, the dose of SFTSV antigen for mouse immunization is from about 100 ng to about 5 pg. In some examples, the dose of SFTSV antigen for human administration is from about 0.1 pg to about 5000 pg total antigen. In further examples, the dose is from about 1 pg to about 2.0 mg, from about 100 pg to about 1 mg, from about 200 pg to about 800 pg, from about 250 pg to about 750 pg, or about 500 pg total antigen.
[0076] In some examples, the composition is administered with a pharmaceutically acceptable carrier, excipient, buffer, stabilizer, cryoprotectant, preservative, or combination thereof. Suitable components include, without limitation, saline, phosphate buffer, citrate buffer, HEPES buffer, sucrose, mannitol, dextrose, polysorbate, cholesterol, phospholipids, polyethylene glycol-lipids, or combinations thereof. In particular examples, the composition comprises sucrose, mannitol, HEPES buffer, or a combination thereof.
[0077] In some examples, the method comprises preparing the composition before administration by contacting a polyhistidine-tagged SFTSV antigen with a CoPoP-containing liposome under conditions sufficient for the antigen to associate with the liposome. The resulting composition may comprise a liposome-bound SFTSV antigen displayed on theliposome surface. In some examples, the contacting step is performed without a covalent coupling reaction, without a maleimide reactive group, without a succinimidyl ester reactive group, without an exogenous catalyst, and without a non-canonical amino acid.
[0078] In some examples, the composition is administered alone. In other examples, the composition is administered in combination with one or more additional agents. The additional agent may comprise another vaccine, another immunogenic composition, an antiviral agent, an immune modulator, an adjuvant, or a supportive-care agent. The additional agent may be administered before, after, or concurrently with the composition described herein.
[0079] In some examples, the immune response elicited by the method is evaluated by measuring antigen-specific antibody titers, SFTSV-neutralizing antibody titers, binding to an SFTSV antigen, binding to SFTSV Gn, binding to a conformational epitope, neutralization of one or more SFTSV strains, reduction in viral load, reduction in disease severity, reduction in one or more clinical symptoms, or survival following SFTSV exposure.
[0080] The present disclosure provides methods for using structures bearing the bilayers as described herein. In one example, this disclosure provides a method of eliciting an immune response in a host. The immune response may generate antibodies. The method comprises administering to a subject a composition comprising a structure bearing CoPoP bilayers to which is conjugated a histidine tagged antigen. The compositions may be administered by any standard route of immunization including subcutaneous, intradermal, intramuscular, intratumoral, or any other route. The compositions may be administered in a single administration or may be administered in multiple administrations including booster shots. Antibody titres can be measured to monitor the immune response.
[0081] The vaccine compositions may comprise one or more adjuvants. The vaccine compositions can comprise additives, such as diluents, adjuvants, excipients, or carriers. Such additives can be liquids, such as water, oils, saline, glucose or the like, and auxiliary, stabilizing, thickening, or lubricating agents, wetting or emulsifying agents, or pH buffering agents, gelling or viscosity enhancing additives, detergents and solubilizing agents (e.g., TWEEN® 20, TWEEN® 80 also referred to as polysorbate 20 or 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol), bulking substances (e.g., lactose, mannitol), flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. See Remington: The Science and Practice of Pharmacy (2012) 22ndEdition. Non-aqueous solvents or vehicles can be used such as propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and com oil, gelatin,and injectable organic esters such as ethyl oleate. The formulations may be lyophilized and redissolved or resuspended just before use. The formulation may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.
[0082] In an aspect, the present disclosure provides methods to inducing a subdomain III immune response in a subject.
[0083] The method may be performed on or in a subject in need of treatment. The subject to be treated by the method of the disclosure may be human or non-human (e.g., mammal). Non-human animals include ungulates such as bovines. Additional on-limiting examples of non-human mammals include pigs, mice, rats, rabbits, cats, dogs, or other agricultural mammals, pet, or service animals, and the like.
[0084] The compositions can be introduced or administered into a subject using any suitable administration route, including, but not limited to parenteral, subcutaneous, intraperitoneal, intramuscular, intravenous, mucosal, topical, intradermal, and oral administration.
[0085] Immunization can be done by way of a single dose, or it can be done by multiple doses that are spaced apart. For example, an initial administration and subsequent booster doses can be used. The compositions can be administered alone or can be coadministered or sequentially administered with other prophylactic (such as, for example, other immunogenic compositions) or therapeutic compositions (such as, for example, chemotherapeutic agents).
[0086] The dose of peptide fragment (e.g., SD2 / 3 or SD / 1 / 23) needed for mice immunization are in a range from 100 ng to 5 pg, including all 0.1 ng values and ranges therebetween. The expected human dosing of the peptide fragment (e.g., SD2 / 3 or SD / 1 / 23) may be 0.1-5000 pg, total peptide dose. In examples, the total peptide dose may be 1 pg to 2.0 mg. For example, the dose may be 100 pg to 1 mg. In examples, the dose may be 200 to 800 pg or or 250 to 750 pg or about 500 pg.
[0087] The steps of the method described in the various embodiments and examples disclosed herein are sufficient to carry out the methods of the present invention. Thus, in an embodiment, the method consists essentially of a combination of the steps of the methods disclosed herein. In another embodiment, the method consists of such steps.
[0088] The following Statements provide various examples of the present disclosure. They are not intended to be limiting in any way.Statement 1. A vaccine composition comprising:a) a plurality of liposomes, each liposome comprising:i) a bilayer, wherein the bilayer comprises A) one or more phospholipids andwherein cobalt is chelated to the porphyrin or B) one or more phospholipids a porphyrin having cobalt chelated thereto; andii) a SFTSV Gn or Gc protein (e.g., a recombinant SFTSV Gn or Gc protein) having a polyHis-tag positioned within the protein, wherein the His-tag comprises four or more consecutive histidine residues and the protein is coupled to liposomes containing cobalt-porphyrinb) a pharmaceutical carrier.Statement 2. A vaccine composition according to Statement 1, wherein the Gn antigen is SD2 / 3 or SD 1 / 2 / 3.Statement 3. A vaccine composition according to Statement 1 or Statement 2, wherein the vaccine elicits SFTSV neutralizing antibodies.Statement 4. A vaccine composition according to any one of the preceding Statements, further comprising one or more adjuvants (e.g., attenuated lipid A derivatives, phosphorylated hexaacyl disaccharide (PHAD), MPLA, and / or QS21).Statement 5. A vaccine composition according to Statement 4, wherein the one or more adjuvants are PHAD-3D6A, MPLA, EcML, QS21, CL401, QS18 , QuilA, QS7, DDAB, CL401, CL413, CL429, 3M052, Resiquimod (R848), Alpha-gal-cer, DSR-6434, 3M-002(CL075), Selgantolimod, Motolimod, STING-Agonist-1, Kdo2-lipidA, or any combination thereof.Statement 6. The vaccine composition according to any one of the preceding Statements, wherein the cobalt porphyrin-phospholipid conjugate makes up from 0.1 to 25 mol % of the bilayer, including all 0.01 mol % values and ranges therebetween (e.g., 5 to 10 mol % of the bilayer).Statement 7. A vaccine composition according to any one of the preceding Statements, wherein the cobalt porphyrin-phospholipid conjugate makes up from 5 to 10 mol % of the bilayer.Statement 8. A vaccine composition according to any one of the preceding Statements, wherein the polyHis-tag comprises 4, 5, 6, or 7 histidine residues.Statement 9. A vaccine composition according to any one of the preceding Statements, wherein the size of the liposome is 50 nm to 200 nm, including every nm value and range therebetween.Statement 10. A vaccine composition according to any one of the preceding Statements, further comprising one or more adjuvants that are not associated with the liposomes.Statement 11. A method for eliciting neutralizing antibodies SFTSV.Statement 12. A method for inducing a subdomain III immune response comprising administering to the subject a vaccine composition according to any one of Statements 1-9. Statement 13. A method according to Statement 12, wherein the vaccine composition is administered one or more times.Statement 14. A method according to Statement 12 or Statement 13, wherein severe fever with thrombocytopenia syndrome is inhibited or partially inhibited or reduced in the subject. Statement 15. The vaccine composition according to any one of Statements 1-10, wherein the recombinant SFTSV Gn or Gc protein is a recombinantSFTSV Gn protein comprising subdomain I, subdomain II, and subdomain III of SFTSV Gn. Statement 16. A vaccine composition according to Statement 15, wherein the recombinant SFTSV Gn protein comprises a C-terminal polyHis-tag.Statement 17. A vaccine composition according to Statement 15 or Statement 16, wherein the recombinant SFTSV Gn protein comprises G-4H, G-5H, G-6H, G-7H, 6H-G, or 7H-G.Statement 18. A vaccine composition according to any one of Statements 1-10 or 15-17, wherein the recombinant SFTSV Gn or Gc protein comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 1-9.Statement 19. A vaccine composition according to any one of Statements 1-10 or 15-18, wherein the recombinant SFTSV Gn or Gc protein comprises a secretion signal (e.g., any one of SEQ ID NOs: 10-13).Statement 20. A vaccine composition according to Statement 19, wherein the secretion signal comprises an AZCLD secretion signal or a TIMP1 secretion signal.Statement 21. A vaccine composition according to any one of Statements 1-10 or 15-20, wherein the recombinant SFTSV Gn or Gc protein comprises a polyHis-tag positioned at a C-terminus of the protein.Statement 22. A vaccine composition according to any one of Statements 1-10 or 15-21, wherein the recombinant SFTSV Gn or Gc protein comprises a polyHis-tag positioned at an N-terminus of the protein.Statement 23. A vaccine composition according to any one of Statements 1-10 or 15-22, wherein the recombinant SFTSV Gn or Gc protein is non-covalently coupled to the liposomes through cobalt-histidine coordination.Statement 24. A vaccine composition according to any one of Statements 1-10 or 15-23, wherein at least a portion of the polyHis-tag resides in a hydrophobic portion of the liposome bilayer.Statement 25. A vaccine composition according to any one of Statements 1-10 or 15-24, wherein at least a portion of the recombinant SFTSV Gn or Gc protein is exposed on an exterior surface of the liposome.Statement 26. A vaccine composition according to any one of Statements 1-10 or 15-25, wherein the liposomes comprise DOPC and cholesterol.Statement 27. A vaccine composition according to any one of Statements 1-10 or 15-26, wherein the liposomes comprise CoPoP, PHAD-3D6A, and QS-21.Statement 28. A vaccine composition according to any one of Statements 1-10 or 15-27, wherein the liposomes have a diameter of about 30 nm to about 250 nm.Statement 29. A vaccine composition according to any one of Statements 1-10 or 15-28, wherein the liposomes have a diameter of about 100 nm to about 175 nm.Statement 30. A vaccine composition according to any one of Statements 1-10 or 15-29, wherein the composition comprises a buffer having a pH of about 5 to about 9.Statement 31. A vaccine composition according to any one of Statements 1-10 or 15-30, wherein the composition comprises HEPES buffer.Statement 32. A vaccine composition according to any one of Statements 1-10 or 15-31, wherein the composition comprises sucrose, mannitol, or a combination thereof.Statement 33. A vaccine composition according to Statement 32, wherein sucrose or mannitol is present at a concentration effective to preserve reactivity of the recombinant SFTSV Gn or Gc protein with a neutralizing antibody after storage.Statement 34. A vaccine composition according to any one of Statements 1-10 or 15-33, wherein the vaccine composition is lyophilized.Statement 35. A vaccine composition according to any one of Statements 1-10 or 15-34, wherein the vaccine composition is formulated for intramuscular administration.Statement 36. A vaccine composition according to any one of Statements 1-10 or 15-35, wherein the vaccine composition is formulated for mucosal or intranasal administration. Statement 37. A vaccine composition according to any one of Statements 1-10 or 15-36, wherein the vaccine composition elicits antibodies that neutralize a homologous SFTSV strain and a heterologous SFTSV strain.Statement 38. A vaccine composition according to any one of Statements 1-10 or 15-37, wherein the vaccine composition elicits antibodies that bind a conformational epitope of SFTSV Gn.Statement 39. A method of making a vaccine composition, themethod comprising contacting a recombinant SFTSV Gn or Gc protein comprising a polyHis-tag with a plurality of liposomes comprising cobalt-porphyrin-phospholipid under conditions sufficient for the recombinant SFTSV Gn or Gc protein to associate with the liposomes. Statement 40. A method according to Statement 39, wherein the association occurs without covalent conjugation chemistry.Statement 41. A method according to Statement 39 or Statement 40, wherein the recombinant SFTSV Gn or Gc protein is contacted with the liposomes by admixture.Statement 42. A method according to any one of Statements 39-41, wherein the liposomes comprise CoPoP, PHAD or PHAD-3D6A, and QS-21.Statement 43. A method according to any one of Statements 39-42,further comprising formulating the liposomes associated with the recombinant SFTSV Gn or Gc protein with a pharmaceutically acceptable carrier.Statement 44. A method according to any one of Statements 39-43, furthercomprising formulating the liposomes associated with the recombinant SFTSV Gn or Gc protein with HEPES buffer, sucrose, mannitol, or a combination thereof.Statement 45. A method of eliciting an immune response against SFTSV in a subject, the method comprising administering to the subject an effective amount of the vaccine composition according to any one of Statements 1-10 or 15-38.Statement 46. A method according to Statement 45, wherein the immune response comprises production of SFTSV-neutralizing antibodies.Statement 47. A method according to Statement 45 or Statement 46, wherein the immune response comprises production of antibodies that bind SFTSV Gn subdomain III.Statement 48. A method according to any one of Statements 45-47, wherein the vaccine composition is administered intramuscularly.Statement 49. A method according to any one of Statements 45-48, wherein the vaccine composition is administered as a first dose and one or more booster doses.Statement 50. A method according to any one of Statements 45-49, wherein the subject is a human.Statement 51. A method according to any one of Statements 45-49, wherein the subject is a non-human mammal.Statement 52. A method according to any one of Statements 45-51, wherein the vaccine composition comprises about 0.1 pg to about 5000 pg total antigen.Statement 53. A method according to any one of Statements 45-52, wherein the vaccine composition comprises about 100 pg to about 1 mg total antigen.Statement 54. A method according to any one of Statements 45-53, wherein Severe Fever with Thrombocytopenia Syndrome is inhibited, reduced, or prevented in the subject.Statement 55. A kit comprising the vaccine composition according to any one of Statements 1-10 or 15-38 and instructions for administering the vaccine composition to a subject to elicit an immune response against SFTSV.Statement 56. A kit according to Statement 55, wherein the vaccine composition comprises a first container comprising CoPoP-containing liposomes and a second container comprising a recombinant SFTSV Gn or Gc protein comprising a polyHis-tag.Statement 57. A kit according to Statement 56, wherein the instructions direct contacting the recombinant SFTSV Gn or Gc protein with the CoPoP-containing liposomes before administration.
[0089] The following examples are presented to illustrate the present disclosure. They are not intended to be limiting in any matter.EXAMPLE 1
[0090] This example provides a description of compositions of the present disclosure.
[0091] SNAP enables vaccine development based on spontaneous formation of potent and biostable nanoparticle vaccines using his-tagged recombinant antigens with simple admixture. In general, display of antigens on nanoliposomes leads to improved antigen delivery to antigen-presenting cells, and presentation of the antigen to B cells in a uniformly oriented arrayed fashion. The use of his-tagged antigens themselves in vaccines simplifies antigen purification, further accelerating vaccine development with improved antigen quality. The short his-tag is buried and mutes its immunogenicity in CoPoP liposomes and furthermore does not elicit anti-his-tag antibodies in humans. SNAP improves the focus of antigen-specific immune responses. Viral vectors, conjugate vaccines, and engineered viruslike particles (VLPs) incorporate a substantial amount of vector- or scaffold- derived protein, and indeed for many vaccine platforms, the majority of the protein content of the vaccine is the scaffold, not the actual antigen. This leads to irrelevant and / or undesirable immune responses against the scaffold, vector, or carrier protein that are often immunodominant, which can also preclude multiple boosting strategies. As the SNAP liposome system contains no protein itself, immune responses are directed against the protein antigen of interest and not the SNAP liposome scaffold. The SNAP system can incorporate lipid-phase adjuvants such as MPLA and QS-21 in the bilayer. As a result, adjuvants and antigens are co-delivered toimmune cells in draining lymph nodes. This is advantageous to co-mixing approaches that result in variable antigen and adjuvant co-delivery that depends on factors such as injection volume, and individual draining lymph node geometries. Owing to its potency, SNAP vaccines offer substantial possibility for dose sparing, to facilitate vaccine production.Finally, the SNAP system is versatile in numerous other senses. For example, it enables simple generation of multivalent vaccines with ease. It is also amenable to lyophilization and intranasal delivery.
[0092] The concept of this is shown in FIG. 1, SNAP enables biostable display of His-tagged antigens such as His-tagged SFTS Gn on the surface of immunogenic liposomes.
[0093] SFTSV has two envelope glycoproteins, Gc and Gn that form a typical class II viral fusion protein to mediate host cell entry. Gn has emerged as a target for SFTS vaccine countermeasures and mRNA vaccines encoding Gn have been shown to elicit neutralizing antibodies that are protective in murine challenge models and a DNA vaccine encoding Gn / Gc was shown to confer protection in a ferret model. Given the need to develop countermeasures for SFTS, a SNAP vaccine based on the Gn antigen was developed.
[0094] As shown in FIG. 2A, the structure of Gn comprises multiple domains, with the potent neutralizing monoclonal antibody Mab 4-5 recognizing an epitope in subdomain III. Various constructs were expressed that included subdomain III from SFTSV (HB29 strain; NC 018138.1), namely SD3, which included only Gn subdomain III; SD2 / 3, which included Gn subdomains II and III; and SD1 / 2 / 3, which included all three Gn subdomains (FIG. 2B). All sequences were derived from the HB29 strain. A C-terminal his-tag was appended for purification (and SNAP display) and two different N-terminal secretion signals were assessed, AZCLD or TIMP1. Proteins were expressed in CHO cells with transient transfection by Genscript and purified by Ni-NTA chromatography. As shown in FIG. 2C, SD3 alone did not yield satisfactory yield to clearly be visualized on SDS-PAGE. Both SD2 / 3 and SD 1 / 2 / 3 provided sufficient protein for further study, with SD 1 / 2 / 3 with TIMP1 signal sequence providing a high yield of protein. Indeed, subsequent expression data with 100 mL of culture has yielded 4 separate batches of proteins with -60-80 mg of pure SD 1 / 2 / 3 protein, a remarkably high protein yield compared to about a dozen other antigens that had been expressed.
[0095] Next, it was assessed whether SD2 / 3 and SD 1 / 2 / 3 could be displayed on SNAP liposomes. As shown in FIG. 3 A, following simple admixture both SD2 / 3 and SD1 / 2 / 3 effectively bound to SNAP liposomes, as judged by a Ni-NTA bead competition assay. These SNAP liposomes contained CoPoP, PHAD-3D6A, and QS-21 and are referredto as CPQ liposomes. Details about the synthesis of CoPoP, as well as the chemical structures of these particular adjuvants in CPQ have been reported by us previously. As shown in FIG.3B, CPQ liposomes displaying SD2 / 3 and SD1 / 2 / 3 were approximately 110 nm in diameter, consistent with prior SNAP formulations and sufficiently small to be compatible with sterile filtration processes. Antigen reactivity was next assessed in soluble or liposome-bound format with the neutralizing MAb 4-5 antibody, obtained from Absolute Antibody (catalog # Ab03836-10.0). As shown in FIG. 3C, only SD1 / 2 / 3 was reactive with MAb 4-5. This suggests that proper folding of domain III required domain I as well. SD1 / 2 / 3 was reactive with MAb 4-5 either in soluble format or when displayed on the surface of CPQ liposomes (FIG. 3C).
[0096] Also assessed was the biochemical stability of SD 1 / 2 / 3 either when displayed on CPQ liposomes or in PBS. As shown in FIG. 4, SD1 / 2 / 3 was resistance to proteolytic degradation in either scenario. At room temperature no degradation was observed with SD1 / 2 / 3 either on immunogenic liposomes (FIG. 4A) or in PBS solution (FIG. 4B) for 4-weeks of stability testing.
[0097] Next, outbred CD-I mice were immunized with either SD2 / 3 or SD 1 / 2 / 3 admixed with either CPQ (CoPoP / PHAD / QS-21) liposomes, or control liposomes that contain the same potent adjuvants but do not induce particle formation as the cobalt is replaced with 2 hydrogens (2HPQ liposomes). Alum was used as an additional control. 2 pg of SD1 / 2 / 3 was immunized intramuscularly on day 0 and day 14. As shown in FIG. 5A, SD2 / 3 and SD 1 / 2 / 3 showed the highest antigen-specific IgG titer when admixed with CPQ liposomes, compared to 2HPQ liposomes (non-particle forming) or Alum. These sera were used in a SFTS neutralization assay. As shown in FIG. 5B, with the homologous HB29 strain, neutralization was only observed with SD 1 / 2 / 3 post-vaccine sera. SD2 / 3 did not give rise to any neutralizing antibodies. Furthermore, CPQ gave rise to the highest level of nAb titer, demonstrating that liposome display using SNAP benefits the SD 1 / 2 / 3 antigen. These results were further confirmed with the neutralization of the HG1 (China) strain, a heterologous viral strain compared to the vaccine antigen (FIG. 5C), with a similar pattern observed with SD 1 / 2 / 3 adjuvanted with CPQ providing the highest level of neutralization, and SD2 / 3 not giving rise to any neutralizing antibodies at all.EXAMPLE 2
[0098] This example provides a description of compositions of the present disclosure.
[0099] SNAP offers several advantages for vaccine development. As shown in FIG.1, SNAP enables biostable display of his-tagged antigens such as his-tagged SFTS Gn on the surface of immunogenic liposomes.
[0100] SFTSV has two envelope glycoproteins, Gc and Gn that form a typical class II viral fusion protein to mediate host cell entry. Gn has emerged as a target for SFTS vaccine countermeasures and mRNA vaccines encoding Gn have been shown to elicit neutralizing antibodies that are protective in murine challenge models and a DNA vaccine encoding Gn / Gc was shown to confer protection in a ferret model. Given the need to develop countermeasures for SFTS, a SNAP vaccine based on the Gn antigen was developed and described herein.
[0101] The structure of Gn comprises multiple domains, with the potent neutralizing monoclonal antibody Mab 4-5 recognizing an epitope in subdomain III. Various constructs were expressed that included subdomain III from SFTSV (HB29 strain; NC 018138.1), namely G3-6H, which included only Gn subdomain III; G23-6H, which included Gn subdomains II and III; and G-6H, which included all three Gn subdomains (FIG. 6A). All sequences were derived from the HB29 strain. A C-terminal His-tag was appended for purification (and SNAP display) and two different N-terminal secretion signals were assessed, AZCLD or TIMP1. Proteins were expressed in CHO cells with transient transfection by Genscript and purified by Ni-NTA chromatography. As shown in FIG. 6B and FIG. 6C, G3-6H alone did not yield satisfactory yield to clearly be visualized on SDS-PAGE. Both G23-6H and G-6H provided sufficient protein for further study, with SD1 / 2 / 3 with TIMP1 signal sequence providing a high yield of protein. Next, various His-tagged constructs were developed with varying position and number of histidine residues in the his-tag (FIG.6D). The yield of the constructs generally increased with increasing his-tag length, however all constructs provided for strong protein yields, that resulted in good protein purity as judged by SDS PAGE (FIG. 2E). Probing reactivity with an anti-his-tag antibody revealed that the G-4H construct, with only 4 histidine residues was not reactive with the antibody.
[0102] The sequence of G-6H, with the TIMP1 secretion signal is shown in Table 1 herein.
[0103] Next, whether the various G constructs could be displayed on SNAP liposomes was assessed. As shown in FIG. 7A, all G constructs effectively bound to SNAP liposomes. These SNAP liposomes contained CoPoP, PHAD-3D6A, and QS-21 and are referred to as CPQ liposomes. Details about the synthesis of CoPoP, as well as the chemical structures of these particular adjuvants in CPQ have been reported by us previously. Asshown in FIG. 7B, CPQ liposomes G were approximately 100 nm in diameter, consistent with prior SNAP formulations and sufficiently small to be compatible with sterile filtration processes. Polydispersity indices were all less than 0.4 (FIG. 7C). G and G23 were assessed for antigen reactivity with the neutralizing MAb 4-5 antibody, obtained from Absolute Antibody (catalog # Ab03836-10.0). As shown in FIG. 3D, G-6H was reactive with the antibody, but G23-6H was not. This suggests that proper folding of domain III required domain I as well. As shown in FIG. 7D, in PBS, all G constructs were reactive with MAb 4-5. Unexpectedly, reactivity for the N-terminally his tagged constructs, 6H-G and 7H-G was attenuated when these proteins bound to the liposomes (FIG. 7E and 7F). All C-terminally his-tagged constructs remained reactive on liposome surfaces with the neutralizing antibody.
[0104] Also assessed was the biochemical stability of G-6H either when displayed on CPQ liposomes or in PBS. As shown in FIG. 8A, G-6H was resistance to proteolytic degradation in either scenario. At room temperature no degradation was observed with G-6H either on immunogenic liposomes or in PBS solution for 4-weeks of stability testing. Particle size remained stable during storage as well (FIG. 8B).
[0105] Next, outbred CD-I mice were immunized with either SD2 / 3 or SD 1 / 2 / 3 admixed with either CPQ (CoPoP / PHAD / QS-21) liposomes, or control liposomes that contain the same potent adjuvants but do not induce particle formation as the cobalt is replaced with 2 hydrogens (2HPQ liposomes). Alum was used as an additional control. 2 pg of SD1 / 2 / 3 was immunized intramuscularly on day 0 and day 14. As shown in FIG. 9A, SD2 / 3 and SD 1 / 2 / 3 showed the highest antigen-specific IgG titer when admixed with CPQ liposomes, compared to 2HPQ liposomes (non-particle forming) or Alum. SFTS neutralization assay was carried out as described. As shown in FIG. 9B, with the homologous HB29 strain, neutralization was only observed with SD 1 / 2 / 3 post-vaccine sera. SD2 / 3 did not give rise to any neutralizing antibodies. Furthermore, CPQ gave rise to the highest level of nAb titer, demonstrating that liposome display using SNAP benefits the SD 1 / 2 / 3 antigen. These results were further confirmed with the neutralization of the HG1 (China) strain, a heterologous viral strain compared to the vaccine antigen (FIG. 9C), with a similar pattern observed with SD 1 / 2 / 3 adjuvanted with CPQ providing the highest level of neutralization, and SD2 / 3 not giving rise to any neutralizing antibodies at all.
[0106] Next, the various His-tagged G antigens were assessed for immunogenicity and neutralization. The same immunization conditions were used. As shown in FIG. 10 A, all constructs gave rise to G-specific antibodies. The Alum group had significantly less titer compared to the CPQ groups. As shown in FIG. 10B, the sera also had strong neutralizingactivity against both SFTSV strains. Alum was not as effective as CPQ to elicit neutralizing antibodies. When the neutralization against HB29 is considered, the N-terminally tagged G constructs had diminished neutralization compared to the C-terminally tagged constructs. This may be that the antigen does not expose neutralizing epitopes as effectively, which reflects the slot blot data shown in Fig 7F.
[0107] At elevated temperatures, the G-6H antigen on its own or bound to CoPoP liposomes may lose conformational stability. It was found that Gn-H6 lost reactivity with the neutralizing antibody MAb 4-5 at 37 °C over a period of two days. Various buffer conditions of CoPoP -bound Gn-H6 were assessed. After two days at 37 °C, the Gn-H6 bound to CoPoP liposomes in PBS lost MAb 4-5 reactivity (condition #1 in FIG. 11). Other conditions improved MAb 4-5 reactivity at the same storage conditions. Sucrose and mannitol, two well-known cryo-protectants improved reactivity, especially at elevated concentrations of50 mg / mL. The use of HEPES buffer also improved MAb 4-5 reactivity relative to Tris or phosphate buffers. Therefore, storage of the liposomal vaccine in sucrose, mannitol or related saccharides could be considered for long term storage, as could use of HEPES buffer.
[0108] Although the present disclosure has been described with respect to one or more particular embodiments and / or examples, it will be understood that other embodiments and / or examples of the present disclosure may be made without departing from the scope of the present disclosure.
Claims
CLAIMS:
1. A vaccine composition comprising:a) a plurality of liposomes, each liposome comprising:i) a bilayer, wherein the bilayer comprises A) one or more phospholipids andwherein cobalt is chelated to the porphyrin or B) one or more phospholipids a porphyrin having cobalt chelated thereto; andii) a SFTSV Gn or Gc protein having a polyHis-tag positioned within the protein, wherein the His-tag comprises four or more consecutive histidine residues and the protein is coupled to liposomes containing cobalt-porphyrinb) a pharmaceutical carrier.
2. The vaccine composition of claim 1, wherein the recombinant SFTSV Gn or Gc protein comprises an SFTSV Gn antigen comprising SD2 / 3 or SD 1 / 2 / 3.
3. The vaccine composition of claim 1, wherein the recombinant SFTSV Gn or Gc protein is a recombinant SFTSV Gn protein comprising subdomain I, subdomain II, and subdomain III of SFTSV Gn.
4. The vaccine composition of claim 3, wherein the recombinant SFTSV Gn protein comprises a C-terminal polyHis-tag.
5. The vaccine composition of claim 3, wherein the recombinant SFTSV Gn protein comprises G-4H, G-5H, G-6H, G-7H, 6H-G, or 7H-G.
6. The vaccine composition of claim 1, wherein the recombinant SFTSV Gn or Gc protein is any one of SEQ ID NOs: 1-9.
7. The vaccine composition of claim 1, wherein the recombinant SFTSV Gn or Gc protein comprises an amino acid sequence having at least 80% sequence identity to a sequence selected from SEQ ID NOs: 1-9.
8. The vaccine composition of claim 1, wherein the recombinant SFTSV Gn or Gc protein comprises a secretion signal.
9. The vaccine composition of claim 8, wherein the secretion signal comprises an AZCLD secretion signal or a TEMPI secretion signal.
10. The vaccine composition of claim 1, wherein the polyHis-tag comprises 4, 5, 6, or 7 histidine residues.
11. The vaccine composition of claim 1, wherein the polyHis-tag is positioned at a C-terminus of the recombinant SFTSV Gn or Gc protein.
12. The vaccine composition of claim 1, wherein the polyHis-tag is positioned at an N-terminus of the recombinant SFTSV Gn or Gc protein.
13. The vaccine composition of claim 1, wherein the recombinant SFTSV Gn or Gc protein is non-covalently coupled to the liposomes through cobalt-histidine coordination.
14. The vaccine composition of claim 1, wherein at least a portion of the polyHis-tag resides in a hydrophobic portion of the bilayer.
15. The vaccine composition of claim 1, wherein at least a portion of the recombinant SFTSV Gn or Gc protein is exposed on an exterior surface of the liposomes.
16. The vaccine composition of claim 1, wherein a cobalt porphyrin-phospholipid conjugate makes up from 0.1 mol % to 25 mol % of the bilayer.
17. The vaccine composition of claim 16, wherein the cobalt porphyrin-phospholipid conjugate makes up from 5 mol % to 10 mol % of the bilayer.
18. The vaccine composition of claim 1, wherein the liposomes comprise 1,2-dioleoyl-sn-glycero-3 -phosphocholine (DOPC) and cholesterol.
19. The vaccine composition of claim 1, further comprising one or more adjuvants.
20. The vaccine composition of claim 19, wherein the one or more adjuvants comprise PHAD-3D6A, MPLA, EcML, QS21, CL401, QS18, QuilA, QS7, DDAB, CL413, CL429, 3M052, Resiquimod (R848), Alpha-gal-cer, DSR-6434, 3M-002 (CL075), Selgantolimod, Motolimod, STING-Agonist-1, Kdo2-lipidA, or any combination thereof.
21. The vaccine composition of claim 19, wherein the liposomes comprise CoPoP, PHAD-3D6A, and QS-21.
22. The vaccine composition of claim 1, wherein the liposomes have a diameter of about 30 nm to about 250 nm.
23. The vaccine composition of claim 1, wherein the composition comprises HEPES buffer, sucrose, mannitol, or a combination thereof.
24. The vaccine composition of claim 1, wherein the vaccine composition is lyophilized.
25. A method of making a vaccine composition, the method comprising contacting a recombinant SFTSV Gn or Gc protein comprising a polyHis-tag with a plurality of liposomes comprising cobalt-porphyrin-phospholipid under conditions sufficient for the recombinant SFTSV Gn or Gc protein to associate with the liposomes.
26. The method of claim 25, wherein the association occurs without covalent conjugation chemistry.
27. The method of claim 25, further comprising formulating the liposomes associated with the recombinant SFTSV Gn or Gc protein with a pharmaceutically acceptable carrier.
28. A method of eliciting an immune response against SFTSV in a subject, the method comprising administering to the subject an effective amount of the vaccine composition of claim 1.
29. The method of claim 28, wherein the immune response comprises production of SFTSV-neutralizing antibodies or antibodies that bind SFTSV Gn subdomain III.
30. A kit comprising a vaccine composition of claim 1 and instructions for administering the vaccine composition to a subject to elicit an immune response against SFTSV.
